These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26753880)

  • 1. (18)F-fluoride positron emission tomography/computed tomography and bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer patients: study protocol for a multicentre, diagnostic test accuracy study.
    Fonager RF; Zacho HD; Langkilde NC; Petersen LJ
    BMC Cancer; 2016 Jan; 16():10. PubMed ID: 26753880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
    Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
    BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer.
    Kjölhede H; Ahlgren G; Almquist H; Liedberg F; Lyttkens K; Ohlsson T; Bratt O
    BJU Int; 2012 Nov; 110(10):1501-6. PubMed ID: 22502982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intra-individual comparison of
    Bénard F; Harsini S; Wilson D; Zukotynski K; Abikhzer G; Turcotte E; Cossette M; Metser U; Romsa J; Martin M; Mar C; Saad F; Soucy JP; Eigl BJ; Black P; Krauze A; Burrell S; Nichol A; Tardif JC
    Lancet Oncol; 2022 Dec; 23(12):1499-1507. PubMed ID: 36343655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT.
    Poulsen MH; Petersen H; Høilund-Carlsen PF; Jakobsen JS; Gerke O; Karstoft J; Steffansen SI; Walter S
    BJU Int; 2014 Dec; 114(6):818-23. PubMed ID: 24314065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Prospective Comparison of
    Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
    Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer.
    Wondergem M; van der Zant FM; van der Ploeg T; Knol RJ
    Nucl Med Commun; 2013 Oct; 34(10):935-45. PubMed ID: 23903557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
    Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
    J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of
    Mogensen AW; Petersen LJ; Torp-Pedersen C; Nørgaard M; Pank MT; Zacho HD
    BMJ Open; 2022 Jun; 12(6):e058898. PubMed ID: 35705343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design.
    Gerety EL; Lawrence EM; Wason J; Yan H; Hilborne S; Buscombe J; Cheow HK; Shaw AS; Bird N; Fife K; Heard S; Lomas DJ; Matakidou A; Soloviev D; Eisen T; Gallagher FA
    Ann Oncol; 2015 Oct; 26(10):2113-8. PubMed ID: 26202597
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Wondergem M; van der Zant FM; Knol RJJ; Burgers AMG; Bos SD; de Jong IJ; Pruim J
    World J Urol; 2018 Jan; 36(1):27-34. PubMed ID: 29043431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone metastases from prostate cancer: 18F-fluoride PET/CT in a patient with discordant bone scintigraphy and 11C-choline PET/CT.
    Garcia G; Riera E; Valls E; Soler M; Bassa P; Moragas M; Lomeña F
    Clin Nucl Med; 2013 Feb; 38(2):120-4. PubMed ID: 23334127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-Fluoride positron emission tomography and positron emission tomography/computed tomography.
    Even-Sapir E; Mishani E; Flusser G; Metser U
    Semin Nucl Med; 2007 Nov; 37(6):462-9. PubMed ID: 17920353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. F-18 Sodium Fluoride Positron Emission Tomography/Computed Tomography for Detection of Thyroid Cancer Bone Metastasis Compared with Bone Scintigraphy.
    Lee H; Lee WW; Park SY; Kim SE
    Korean J Radiol; 2016; 17(2):281-8. PubMed ID: 26957915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective comparative study of
    Fonager RF; Zacho HD; Langkilde NC; Fledelius J; Ejlersen JA; Hendel HW; Haarmark C; Moe M; Mortensen JC; Jochumsen MR; Petersen LJ
    Acta Oncol; 2018 Aug; 57(8):1063-1069. PubMed ID: 29447047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No Added Value of
    Zacho HD; Jochumsen MR; Langkilde NC; Mortensen JC; Haarmark C; Hendel HW; Jensen JB; Petersen LJ
    J Nucl Med; 2019 Dec; 60(12):1713-1716. PubMed ID: 31147402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of bone scintigraphy and
    Pyka T; Okamoto S; Dahlbender M; Tauber R; Retz M; Heck M; Tamaki N; Schwaiger M; Maurer T; Eiber M
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2114-2121. PubMed ID: 27290607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma.
    Vaarwerk B; Breunis WB; Haveman LM; de Keizer B; Jehanno N; Borgwardt L; van Rijn RR; van den Berg H; Cohen JF; van Dalen EC; Merks JH
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012325. PubMed ID: 34753195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases.
    Iagaru A; Mittra E; Dick DW; Gambhir SS
    Mol Imaging Biol; 2012 Apr; 14(2):252-9. PubMed ID: 21479710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.